Bellevue Asset Management AG
Bellevue Asset Management AG: Bellevue seeks capital to invest in young, innovative, Swiss biotech companies
EQS Group-News: Bellevue Asset Management AG / Key word(s): Product Launch Media release Küsnacht, 08. February 2018 Bellevue seeks capital to invest in young, innovative, Swiss biotech companies Bellevue Asset Management AG (“Bellevue”), one of the largest financial investment firms in biotech, launches a new venture capital initiative for biotech companies in Switzerland. Despite a leading position in academic life science research, Switzerland lacks institutional venture capital to help efficiently translate its innovative power into local biotech company formation and advance their development. With a new venture capital fund for qualified investors, BB Pureos Bioventures, Bellevue seeks capital to invest in young, innovative drug development companies in Switzerland and abroad. Bellevue launches an initiative for venture capital in Switzerland Bellevue has a long tradition of healthcare investing and is one of the largest and most experienced healthcare investors worldwide. Since 1995, Bellevue has invested in over 80 private healthcare companies through investment vehicles. It recently launched the fundraising for a newly formed investment vehicle, which will invest in 15 to 20 private, innovative drug development companies located in Switzerland and abroad. The fund focuses on companies developing the next generation of biological drugs (“biologics”) for indications with high medical need. Bellevue has assembled a team of seasoned venture capital managers and biotech entrepreneurs supported by a dedicated expert advisory board. «In the past two decades I have witnessed first-hand the importance of institutional venture capital for biotech companies to develop new drugs. Unfortunately, we have too little venture capital in Switzerland, and with our new fund, we are trying to change this», comments Dr. Dominik Escher, founder and former CEO of ESBA Tech, President of the Swiss Biotech Association, and Managing Partner of BB Pureos Bioventures. Dr. Martin Münchbach, Senior Investment Advisor Private Equity at Bellevue and Managing Partner of BB Pureos Bioventures adds: «We have backed great Swiss success stories in the past, like Actelion, Glycart or Molecular Partners. Today we see exciting young companies and projects here that could develop into the success stories of tomorrow». «The companies we have backed developed important new medicines for severe diseases, like Gazyva from Glycart, which received the first breakthrough designation from the US FDA. We want to continue investing in young companies that develop products, which make a significant difference for patients», completes Dr. Klaus Breiner, Senior Investment Advisor Private Equity at Bellevue and Managing Partner of BB Pureos Bioventures.
About Bellevue’s new venture capital fund, BB Pureos Bioventures Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=DAJNAMFJAT Document title: Media release
End of Corporate News |